Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.…
Palvella Therapeutics (PVLA) Stock Looks Above Fair Value After 51% Gain
Palvella Therapeutics (NASDAQ: PVLA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 29 employees.
The shares were at 142.85 USD on 20 November 2026, up 81.7% over 52 weeks. Its 52-week range is 72.22 USD to 179.32 USD: the price is 20.3% below the high and 97.8% above the low.
Its market capitalisation is 2.09B USD.
Palvella Therapeutics reports return on equity of -149.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 211.27M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 16 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 233.44 USD is 63.4% above the current price. The next earnings report is expected on 31 March 2027.